Journal
NEURO-ONCOLOGY
Volume 11, Issue 1, Pages 92-95Publisher
OXFORD UNIV PRESS INC
DOI: 10.1215/15228517-2008-071
Keywords
antiangiogenic drugs; bevacizumab; gastrointestinal perforation; malignant glioma
Categories
Ask authors/readers for more resources
Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this class of drugs is generally well tolerated, rare life-threatening complications, including thromboembolism, hemorrhage, and gastrointestinal (GI) perforation, are reported. We describe six cases of GI perforation among 244 glioma patients (2.5%) during treatment with antiangiogenic agents in combination with chemotherapy and corticosteroids. Two patients succumbed to this complication, and the others recovered. Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints. Neuro-Oncology 11, 92-95, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00073, August 29, 2008. URL http://neuro-oncology.dukejournals.org; DOI: 10.1215/15228517-2008-071)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available